Dr. Andrew Geall has over 20 years of professional experience in the development of drug delivery systems and is a pioneer in the fields of in vitro transcribed (IVT) RNA vaccines and nucleic acid delivery. He is an inventor on 41 patent families, with 505 applications and 203 issued patents in multiple jurisdictions.

Prior to joining Replicate, Andrew held multiple leading positions at Novartis, Avidity Biosciences and Precision NanoSystems Inc. (PNI) focusing on mRNA vaccines, siRNA, formulation, antibody-oligonucleotide conjugate delivery and nanoparticle drugs.  In addition, he was Principal Investigator on a Defense Advanced Research Project Agency (DARPA) contract to develop self-replicating RNA vaccines.

Andrew received his pharmacy degree from the University of Bath in the UK and obtained his PhD at the University of Bath in non-viral gene delivery.